Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.47 |
| ▸ | PYGL | P06737 | 8/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406396 | 0.84 | MEN1 (0.67) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL4938802 | 0.84 | F7 (0.55) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL1203124 | 0.80 | MAPT (0.44) | MEN1KMT2APYGLPOLBMAPT | |
| SCHEMBL12879173 | 0.78 | PYGL (0.53) | MEN1KMT2ANHERF1PYGLPOLB | |
| SCHEMBL6402129 | 0.78 | RXFP1 (0.80) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL6398652 | 0.77 | NHERF1 (0.63) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL1202468 | 0.77 | ATM (0.52) | NHERF1PYGLPOLBATMMAPT | |
| SCHEMBL1203114 | 0.76 | KCNQ3 (0.48) | MEN1KMT2APYGLMAPTCYP1A2 | |
| SCHEMBL1202368 | 0.76 | MAPT (0.47) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL1203032 | 0.75 | KMT2A (0.47) | MEN1KMT2APYGLPOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| EP-1725555-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PROSIDION LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | BRADLEY STUART EDWARD | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269277-A1 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides | PYGL, PDK1, PYGM | MEN1 3942/4885KMT2A 2817/4885RXFP1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.